Today: 29 June 2026
Browse Category

NASDAQ:NTLA 8 October 2025 - 16 June 2026

CRISPR Therapeutics Jumps 12% in New York Trading

CRISPR Therapeutics Jumps 12% in New York Trading

CRISPR Therapeutics shares soared 11.7% to $58.15 after presenting at the Jefferies Global Healthcare Conference, with sector momentum lifting gene-editing stocks and the SPDR S&P Biotech ETF up 3.0%. Casgevy, its key sickle cell therapy, posted $43 million Q1 revenue, but a $122.9 million net loss and biotech risks mean the rally hinges on investor appetite and upcoming clinical updates.
4 June 2026
·······
Intellia Therapeutics Stock Jumps After Hours Ahead of First Phase 3 In Vivo CRISPR Readout

Intellia Therapeutics Stock Jumps After Hours Ahead of First Phase 3 In Vivo CRISPR Readout

Intellia Therapeutics will release Phase 3 data Monday from its HAELO trial of lonvoguran ziclumeran, an in vivo CRISPR gene-editing therapy for hereditary angioedema. The study enrolled 80 patients, testing a single 50 mg infusion against placebo. Intellia shares rose 19.3% after hours Friday ahead of the announcement. The company ended 2025 with $605.1 million in cash and expects it to last into late 2027.
25 April 2026
···
CRISPR Therapeutics stock slides after CFO share-sale filing; JPM conference next

CRISPR Therapeutics stock slides after CFO share-sale filing; JPM conference next

CRISPR Therapeutics shares fell 4.3% to $54.00 after a filing showed CFO Raju Prasad exercised and sold 29,700 shares under a preset trading plan. The move comes ahead of the company’s Jan. 12 slot at the J.P. Morgan Healthcare Conference and an expected mid-February earnings report. Gene-editing peers also traded lower. CASGEVY revenue and rollout remain key investor focus.
9 January 2026
·······
CRISPR Therapeutics stock (CRSP) slips into 2026 as New Year’s Day shuts Wall Street — what investors watch next

CRISPR Therapeutics stock (CRSP) slips into 2026 as New Year’s Day shuts Wall Street — what investors watch next

CRISPR Therapeutics shares closed down 1.4% at $52.44 on Dec. 31, the final trading day of 2025. U.S. markets were shut Jan. 1 for New Year’s. Investors are watching for early-2026 updates on Casgevy’s rollout and the next earnings schedule as trading resumes Jan. 2. Biotech ETFs were little changed in light year-end trading.
2 January 2026
······
Intellia Therapeutics (NTLA) plunges after patient death in pivotal CRISPR trial; Q3 update, analyst downgrades and what to watch next [Nov. 7, 2025]

Intellia Therapeutics (NTLA) plunges after patient death in pivotal CRISPR trial; Q3 update, analyst downgrades and what to watch next [Nov. 7, 2025]

Intellia said a patient in its Phase 3 MAGNITUDE trial died after severe liver toxicity; FDA clinical holds on MAGNITUDE and MAGNITUDE-2 remain. NTLA shares fell as RBC cut its price target to $9, citing increased risk. The company reported $669.9 million in cash and securities, expecting its runway to last into mid-2027. Work continues on its hereditary angioedema program.
7 November 2025
···
Premarket Shock: Why CRISPR Therapeutics Could Move Big Today

Premarket Shock: Why CRISPR Therapeutics Could Move Big Today

The FDA will announce a new fast-track approval process for personalized gene-editing therapies in early November, sending CRISPR Therapeutics shares up 8% and Editas up 12%. CRSP reported over 90% mRNA correction in preclinical CTX460 data and will present Phase 1 CTX310 results at the AHA conference Nov. 8. Intellia paused a TTR amyloidosis trial after a liver injury, causing its stock to fall 46%.
2 November 2025
······
Intellia Stock Crashes on CRISPR Trial Safety Scare – What’s Next After 45% Plunge?

Intellia Stock Crashes on CRISPR Trial Safety Scare – What’s Next After 45% Plunge?

Intellia Therapeutics shares plunged nearly 45% on Oct. 27 after the company halted two Phase 3 trials of its CRISPR therapy due to a patient suffering severe liver toxicity. The stock dropped from the mid-$20s to the low-teens, with NTLA trading around $14–15 as of midday Oct. 28. Several analysts downgraded the stock and cut price targets following the safety incident.
28 October 2025
···
Intellia Therapeutics Stock Plummets 45% After CRISPR Trial Shock – Can Gene-Editing Hopes Survive?

Intellia Therapeutics Stock Plummets 45% After CRISPR Trial Shock – Can Gene-Editing Hopes Survive?

Intellia Therapeutics shares plunged nearly 45% Monday after the company halted two Phase 3 trials of its CRISPR therapy NTLA-2001 due to a severe liver injury in a patient. The stock dropped from about $19 to the low teens, with CRISPR Therapeutics also falling 10%. Intellia paused dosing and enrollment following the Grade 4 liver event and is consulting regulators on next steps.
27 October 2025
···
Beam Therapeutics Stock Soars on Gene-Editing Buzz – Analysts Project Big Upside

Beam Therapeutics Stock Soars on Gene-Editing Buzz – Analysts Project Big Upside

Beam Therapeutics shares jumped 17% to $30.35 on Oct. 20, 2025, marking their highest level since early 2024. The rally followed bullish technical signals and positive clinical updates for its gene-editing therapies. Analysts at Jefferies and H.C. Wainwright reiterated Buy ratings, with price targets up to $80. Beam ended Q2 with $1.2 billion in cash, enough to fund operations into 2028.
20 October 2025
·····
Intellia Therapeutics Stock Soars on Gene-Editing Breakthrough – Analysts Eye 70–100% Upside

Intellia Therapeutics Stock Soars on Gene-Editing Breakthrough – Analysts Eye 70–100% Upside

NTLA surged past $26 on Oct. 8, 2025, after positive Phase 1 data for its ATTR program showed sustained TTR protein knockdown and no new safety issues. Trading volume spiked to 17 million shares. Wall Street remains bullish, with most analysts rating NTLA a Buy and targets averaging $31.7. Intellia holds $630–707 million in cash and expects funding to last into 2027.
9 October 2025
··
Intellia Therapeutics (NTLA) Soars on CRISPR Breakthroughs – Latest Updates & Stock Outlook

Why Intellia Therapeutics’ Stock Could Be a Gene‑Editing Goldmine in 2025 – Deep Dive into NTLA’s Prospects

Intellia shares surged to $26.14 on Oct. 8, up 72.6% over the past month, after Phase 1 data showed its CRISPR therapy reduced serum TTR by 92% at 24 months. The company reported Q2 revenue of $14.2 million and a narrowed net loss per share of $0.98. Cash reserves stood at $630 million. Analyst consensus rates the stock a “Moderate Buy” with targets averaging $27–34.
8 October 2025
··
Intellia Therapeutics (NTLA) Soars on CRISPR Breakthroughs – Latest Updates & Stock Outlook

Intellia Therapeutics (NTLA) Soars on CRISPR Breakthroughs – Latest Updates & Stock Outlook

Intellia’s NTLA-2001 gene editing therapy cut TTR protein by about 90% for three years in transthyretin amyloidosis patients, with improved outcomes and no new safety issues, according to data presented Sept. 25 and published in NEJM. Enrollment finished for the Phase 3 HAELO trial of NTLA-2002, with top-line results expected in 1H 2026. Intellia stock is up over 60% in 2025. Q2 revenue more than doubled to $14.25 million.
8 October 2025
···

Stock Market Today

  • Screen Australia Launches Private Investment Toolkit to Bridge Gap Between Producers and Investors
    June 28, 2026, 9:42 PM EDT. Screen Australia has unveiled a free, interactive Private Investment Toolkit aimed at educating screen producers and potential investors. The digital platform stresses a 'market-informed mindset,' providing guidance on pitching, risk management, value setting, and timelines. It helps investors understand Australia's screen sector, tailor investment strategies, and align goals, covering profit-driven and philanthropic investment paths. Developed with industry experts, the toolkit seeks to demystify private investment, enhance transparency, and standardize practices to foster stronger partnerships. Grainne Brunsdon, COO of Screen Australia, highlighted the toolkit's role in promoting confidence and clarity in screen project investments, ultimately supporting a robust, inclusive industry and talent development.

Latest articles

Trump-era loan caps could open door for private lenders in grad school market

Trump-era loan caps could open door for private lenders in grad school market

29 June 2026
July 1 federal loan caps slash Grad PLUS access, forcing many graduate and professional students to seek private loans; Sallie Mae projects up to 70% origination growth over several years, while SoFi reports record student-loan volume—investors now face a real-time test of how much demand shifts to private lenders as federal limits hit.
IREN Limited (NASDAQ:IREN) slides as Warriors badge faces AI revenue test

IREN Limited (NASDAQ:IREN) slides as Warriors badge faces AI revenue test

29 June 2026
IREN Limited (NASDAQ:IREN) plunged 21.3% to $47.21 over five straight down days despite announcing a record $50M+ annual Warriors jersey deal, as investors focused on the company’s not fully contracted $4.4B target ARR and high short interest at 19.74% of float, with Friday’s close near the lowest analyst target.
Go toTop